The mevalonate pathway in breast cancer biology

Research output: Contribution to journalReview articleContributedpeer-review



Breast cancer affects one in eight women during their lifetime. Although diagnostic and therapeutic options have improved, recurrence, metastasis, and therapeutic resistance remain clinical challenges, which affect life quality and prognosis. The mevalonate pathway is an essential part of cellular homeostasis by providing a number of essential isoprenoid products including cholesterol. However, the disturbance of this pathway paralleled by increased bioavailability of its products and their direct involvement in several steps of tumorigenesis has highlighted the mevalonate pathway as a promising hub in cancer treatment. In this review, we will specifically discuss how the mevalonate pathway affects breast cancer biology in terms of supporting and modulating soluble and cellular factors and distinct steps of tumorigenesis. We will further summarize antitumor effects of the mevalonate pathway-inhibiting drugs, statins and amino-bisphosphonates, in breast cancer and discuss how they are used for future precision therapy.


Original languageEnglish
Article number215761
Pages (from-to)215761
JournalCancer letters
Publication statusPublished - 28 Aug 2022

External IDs

Scopus 85131410080
unpaywall 10.1016/j.canlet.2022.215761
WOS 000810179200005
Mendeley 7b50887c-fc7b-3e04-ac48-557f38d32d0e
ORCID /0000-0002-8691-8423/work/142236006


Research priority areas of TU Dresden

DFG Classification of Subject Areas according to Review Boards

Subject groups, research areas, subject areas according to Destatis

Sustainable Development Goals

ASJC Scopus subject areas


  • Biology, Breast Neoplasms/drug therapy, Cell Transformation, Neoplastic, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Mevalonic Acid/metabolism, Rho-GTPases, Amino-bisphosphonates, Breast cancer, Cholesterol, Statins